Literature DB >> 3028398

Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro.

M Baba, R Pauwels, P Herdewijn, E De Clercq, J Desmyter, M Vandeputte.   

Abstract

2',3'-Dideoxythymidine (ddThd) and its 2',3'-unsaturated derivative 2',3'-dideoxythymidinene (ddeThd) are potent and selective inhibitors of human immunodeficiency virus (HIV) in vitro. When evaluated for their inhibitory effects on the cytopathogenicity of HIV in MT-4 cells, ddThd and ddeThd completely protected the cells against destruction by the virus at a concentration of 1 microM and 0.04 microM, respectively. In this aspect, ddeThd was about 5 times more potent than 2',3'-dideoxycytidine (ddCyd), one of the most potent and selective anti-HIV compounds now pursued for its therapeutic potential in the treatment of AIDS. ddThd and ddeThd also suppressed HIV antigen expression at 1 microM and 0.04 microM, respectively. Their selectivity indexes, as based on the ratio of the 50% cytotoxic dose to the 50% antiviral effective dose, were 120 (ddeThd) and greater than 625 (ddThd).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3028398     DOI: 10.1016/0006-291x(87)90460-8

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  44 in total

Review 1.  Stavudine once daily.

Authors:  Susan M Cheer; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Stavudine: an update of its use in the treatment of HIV infection.

Authors:  M Hurst; S Noble
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of stavudine.

Authors:  K Z Rana; M N Dudley
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

4.  Pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-deoxy-2',3'-didehydrothymidine in rats.

Authors:  F D Boudinot; S G Smith; E D Funderburg; R F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

Review 5.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

6.  Azidothymidine: crystal structure and possible functional role of the azido group.

Authors:  A Camerman; D Mastropaolo; N Camerman
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

7.  Inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxynucleoside triphosphates: template dependence, and combination with phosphonoformate.

Authors:  M C Starnes; Y C Cheng
Journal:  Virus Genes       Date:  1989-05       Impact factor: 2.332

Review 8.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 9.  Clinical pharmacology of zidovudine and other 2',3'-dideoxynucleoside analogues.

Authors:  F Kamali
Journal:  Clin Investig       Date:  1993-05

Review 10.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.

Authors:  J Balzarini
Journal:  Pharm World Sci       Date:  1994-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.